Pfizer Ltd
NSE: PFIZER BSE: 500680
₹4704.50
(-2.06%)
Wed, 11 Mar 2026, 11:57 am
Market Cap220.45B
PE Ratio25.21
Dividend0.73
Health Technology
Pharmaceuticals: Major
24.5KPfizer Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (4.9x coverage).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Pfizer's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Pfizer's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Pfizer is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Pfizer is profitable, therefore cash runway is not a concern.
- Pfizer is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (1292.7%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1219.3x debt.
- Pfizer's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (0.1% vs 0.1% today).
- Interest payments on debt are well covered by earnings (EBIT is 60.2x coverage).
- Pfizer's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
- Low level of unsold assets.
management
- The tenure for the Pfizer board of directors is about average.
- S.'s remuneration is lower than average for companies of similar size in India.
- S.'s compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Pfizer management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Pfizer is not covered by any analysts.
past
- Pfizer has delivered over 20% year on year earnings growth in the past 5 years.
- Pfizer used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Pfizer has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Pfizer's 1-year earnings growth is less than its 5-year average (18.6% vs 25.2%)
- Pfizer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Pfizer's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (18.6% vs 22.7%).
value
- PFIZER outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- PFIZER outperformed the Market in India which returned -14.5% over the past year.
- Pfizer's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Pfizer's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Pfizer is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Pfizer is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Pfizer is overvalued based on earnings compared to the India market.
- NSEI:PFIZER is down -6.8% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:PFIZER is down -6.8% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800